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Abstract
Background: The mechanism underlying autoimmune diabetes has been difficult to define. There
is a strong genetic contribution and numerous studies associate the major histocompatibility
complex, especially the class II region, with predisposition or resistance. However, how these
molecules are implicated remains obscure.
Presentation of the hypothesis: We have supplemented structural analysis with computational
biophysical and sequence analyses and propose an heuristic for distinguishing between human
leukocyte antigen molecules that predispose to insulin dependent diabetes mellitus and those that
are protective. Polar residues at both β37 and β9 suffice to distinguish accurately between class II
alleles that predispose to type 1 diabetes and those that do not. The electrostatic potential within
the peptide binding pocket exerts a strong influence on diabetogenic epitopes with basic residues.
Diabetes susceptibility alleles are predicted to bind autoantigens strongly with tight affinity,
prolonged association and altered cytokine expression profile. Protective alleles bind moderately,
and neutral alleles poorly or not at all. Non-Asp β57 is a modifier that supplements disease risk but
only in the presence of the polymorphic, polar pair at β9 and β37. The nature of β37 determines
resistance on one hand, and susceptibility or dominant protection on the other.
Conclusion: The proposed ideas are illustrated with structural, functional and population studies
from the literature. The hypothesis, in turn, rationalizes their results. A plausible mechanism of
immune mediated diabetes based on binding affinity and peptide kinetics is discussed. The number
of the polymorphic markers present correlates with onset of disease and severity. The molecular
elucidation of disease susceptibility and resistance paves the way for risk prediction, treatment and
prevention of disease based on analogue peptides.
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Background
Insulin dependent diabetes mellitus, juvenile diabetes or
type 1 diabetes is an inheritable and chronic T cell medi-
ated autoimmune disease. T cells attack and destroy beta
cells in the pancreas [OMIM 222100]. The origin or mech-
anism for this self-directed destruction of insulin produc-
ing beta cells has remained elusive and there is no cure.
Mechanisms at the basis of type 2 diabetes are understood
even less. Type 1 diabetes (T1D) is the most common
form of diabetes in children and young people. Its distri-
bution varies by population from 0.1 in 100,000 in China
and Venezuela to about 37 in 100,000 in Sardinia and
Finland. Two recent reviews give an overview of current
understanding, promise and challenge [1,2].
Symptoms accompanying T1D include high levels of glu-
cose in the patient's blood and urine, T cell infiltration
into the pancreas and the presence of autoantibodies
against insulin and beta cell antigens. The antibodies are
under T cell control. Adoptive transfer experiments in ani-
mal models confirm that both CD4+ and CD8+ T cells
play the dominant role in beta cell destruction [3,4]. B
lymphocytes are also important in the pathogenesis of
T1D [5]. Beside making antibody markers for beta cell
destruction, B cells function as an important subset of
antigen presenting cells that maintain the efficient expan-
sion of helper T cells trained on self antigens, as shown in
mice [6].
T1D accounts for 5–10% of the incidence of diabetes in
the United States but has much more severe and debilitat-
ing physical effect on the lives of those affected: secondary
effects include renal disease, eye disease leading to blind-
ness, nerve damage, heart and blood vessel disease that
may lead to amputation, stroke and premature death.
Incidence of T1D is increasing worldwide and there is a
need for better molecular and mechanistic understanding
to enable better treatment and cure.
There is a strong genetic component to T1D. The clearest
association is with the major histocompatibility complex
(MHC) locus on chromosome 6p21, especially the class II
region. DRA-DRB1*0301 (DR3) and -DRB1*0401 (DR4)
are directly implicated as susceptibility molecules [7].
DR3, DR4 or both is present in about 95% of Caucasian
patients [8,9], over twice the distribution of these human
leukocyte antigen (HLA) alleles in the general population.
DQA1*0501-DQB1*0201 (DQ2) and DQA1*0301-
DQB1*0302 (DQ8) are considered another set of high
risk alleles. Some alleles on the other hand are either neg-
atively associated or confer protection. DRB1*1501
(DR15 or DR2b) and DQA1*0102-DQB1*0602
(DQ0602 or DQ6.2) confer strong dominant protection,
even when in combination with alleles with high risk
[10]. The apparent distinction between alleles that predis-
pose their carriers to and those that offer protection in
T1D incriminates HLA molecules themselves as causative
factors. All or almost all autoimmune diseases associate
with the MHC [11]. Nevertheless, not all carriers of the
high risk class II variants develop the disease. Current
opinion is that autoimmune diabetes results from the
complex interaction between many genes and the envi-
ronment with MHC class II region as a major influencing
factor.
The prevailing idea that links the HLA with autoimmune
diabetes is the β57 hypothesis [12]. β57 hypothesis impli-
cates the association of mutations of the strongly con-
served aspartic acid at position 57 of the class II β-chain in
HLA-DQ, to Ala, Val or Ser, with susceptibility to disease.
Crystallographic structures show that the conserved salt
bridge between β57 Asp and the invariant α76 Arg in class
II MHC is broken when β57 Asp is mutated [13-15]. This
mutation has been interpreted to render open the C-ter-
minus of the peptide binding groove, to reduced stability
of class II MHC molecules and to promiscuous peptide
binding [16,17]. DQA1*0301-DQB1*0302 (DQ8) and
DQA1*0501-DQB1*0201 (DQ2), both presumed to pre-
dispose to T1D, lack β57 Asp. Similar arguments have
been made for the mouse non obese diabetes (NOD)
model I-Ag7 molecule considered the equivalent of the
human DQ8 [18,19]. But β57 hypothesis fails to explain
the strong association of DR3 and DR4. DR3 and DR4
retain β57 Asp. While non-Asp β57 alleles are increased in
Caucasian T1D patients [12] other population studies
show overall high prevalence of the conserved β57 Asp in
HLA alleles of diabetics [20-22]. DR and DQ loci are in
tight linkage disequilibrium and this makes it difficult to
delineate the relative contributions of DR and DQ. It was
therefore debated whether DR is also a predisposing locus
[23]. As is now accepted, both DR and DQ contribute to a
neutral response, susceptibility or dominant protection in
T1D [24,25]. DRB1, with DR3 and DR4, has been shown
to be a major susceptibility factor [25,26]. Non-Asp β57
fails to explain the molecular basis of T1D. The thrust of
current research has shifted to genome-wide association
studies.
The promise of structural biology is to elucidate such
structure-function relationship and disease association. A
number of crystallographic structures of class II MHC
molecules associated with autoimmune diseases have
been determined: HLA-DR2 [27,28], -DR3 [29], -DR4
[30], -DQ2 [31], -DQ6 [32], -DQ8 [15], the mouse I-Ak
[33] and I-Ag7 [13,14]. Notwithstanding, the molecular
connection to disease or resistance remains obscure [34-
36]. Our recently reported structure of DRA-DRB3*0101
(DR52a) [37] has kindled our interest in HLA association
with autoimmune diseases. DR52a has the replacement
β57 Asp to Val, a structural similarity to HLA-DQ mole-Biology Direct 2008, 3:42 http://www.biology-direct.com/content/3/1/42
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cules associated with susceptibility. But DR52a is not an at
risk allele with respect to T1D. In the same way, DR7 has
non-Asp β57 and is not associated with T1D. Because of
public health and economic consequences there is interest
in understanding the molecular basis of autoimmune dia-
betes for screening and risk prediction that may lead to
early therapeutic intervention.
Using insight from experimental structure determination
and the evolutionary relationship between class II HLA
molecules [37], we have carried out detailed biophysical
and sequence analyses of class II molecules and inter-
preted the results in the context of published functional
and epidemiological studies the question of HLA link
with T1D. We have identified for the first time and pro-
pose that the physical chemical nature of the polymorphic
residues at β9 and β37 determine class II HLA susceptibil-
ity, resistance or dominant protection in T1D.
Presentation of the hypothesis
We hypothesized and confirmed that differences in poly-
morphic residues in pocket P9 of DR3 and DR52a, closely
related molecules, lead to differences in the charge charac-
ter and epitope selection (not shown). DR3 and DR52a
have overlapping but distinct peptide specificity. While
DR3 is strongly associated with T1D, DR52a is not. The
significant electrostatic difference between DR3 and
DR52a is in their P9 pockets [37]. Following this lead we
compared the respective electrostatic surfaces of DR52a
[37] and DQ8 [15]. DQ8 is strongly associated with T1D.
Electrostatic potentials of the two molecules (without
peptide) were obtained by solving the nonlinear Poisson-
Boltzmann equation (additional file 1) and mapped to
their respective van der Waals surface (Figure 1).
DR52a surface electrostatic potential in pocket P9 is neu-
tral. In clear contrast, the diabetes disposing DQ8 has
high positive potential. We therefore postulate that the
difference at P9 ensues from polarizable polymorphic res-
idues: β9 Glu (in DR52a) versus Tyr (in DQ8) and β37
Phe (in DR52a) versus Tyr (in DQ8). In the structures,
mutation of the strongly conserved β57 Asp breaks the salt
bridge between β57 and the invariant α76 Arg [15,37]. In
DR52a, α76 Arg swings upward and away from pocket P9.
In DQ8 α76 Arg maintains the same lateral axis as the salt
bridge but bends sharply inward toward the peptide P9
residue Glu. β37 in DR52a is hydrophobic (Phe). This
abolishes a crucial hydrogen bond between an acidic pep-
Electrostatic potential map of the P9 pocket Figure 1
Electrostatic potential map of the P9 pocket. Electrostatic potential maps have been calculated separately for DR52a 
and DQ8 without their peptide and mapped to their van der Waals surface. The P9 pockets are shown here with their respec-
tive peptide P9 anchor side chain and selected residues in the pocket superimposed. The DR52a pocket is neutral and DQ8 
shows a highly positive (blue) potential. The difference reflects the preference for a hydrophobic peptide side chain in DR52a 
P9 versus the preference for an acidic side chain in DQ8. The electrostatic difference is hypothesized to be a factor in suscep-
tibility to T1D. Details of the calculations are given under supplementary materials (Additional file 1).Biology Direct 2008, 3:42 http://www.biology-direct.com/content/3/1/42
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tide residue and pocket 9. Therefore DR52a has no prefer-
ence for a peptide acidic residue at P9 [37]. β37 in DQ8 is
Tyr. The difference in orientation of α76 Arg in the two
structures is determined by the nature of β37.
When the peptides are superimposed over their respective
mapped surface, we are struck by the multiple hydrogen
bonds and coupled interactions between DQ8 and insulin
chain B: 9–23 SHLVEALYLVCGERG (P1, P4 and P9
anchors underlined). A network of bonds involving α76
Arg, β37 Tyr, tethered water and β9 Tyr from DQ8 impose
a firm grip on the insulin B peptide at P9 (Figures 1 and
2). β37 Tyr makes a short hydrogen bond to the peptide
P9 residue carboxylate atom (2.73 Å). These unique inter-
actions are hypothesized to result in unusually strong
binding of the peptide and slower dissociation kinetics
leading to an altered cytokine expression profile. Cytokine
expression and CD4+ T cell helper response depend on
peptide-class II MHC-affinity. Limited changes in the res-
idues of the peptide or in the MHC binding site alter the
T cell response: to non-responsiveness, partial response
leading to "anergy" and to differences in proliferation and
cytokine response [38,39].
Hydrogen bond interactions involving insulin B chain P9 anchor in DQ8 Figure 2
Hydrogen bond interactions involving insulin B chain P9 anchor in DQ8. There is a hydrogen bonding network 
involving the insulin peptide glutamic acid anchor and DQ8 α76 arginine, crystallographic water, β37 tyrosine, and β9 tyrosine. 
Two of the bonds from α76 are shown with relaxed constraints. This network of bonds hyper-stabilizes the insulin peptide.Biology Direct 2008, 3:42 http://www.biology-direct.com/content/3/1/42
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Next, we examine to what extent these structural features
found in DQ8 but not in DR52a persist in class II alleles
associated with autoimmune diabetes. We correlate T1D
susceptibility with the electrostatic potential via the three
polymorphic markers: β9, β37 and β57. The heuristic uses
a simple count of polar or charged residues in HLA pocket
P9 as score, surrogate for an exact calculation of the elec-
trostatic potential or count of potential hydrogen bonds
in the absence of atomic coordinates. We compared the
results using epidemiological and genotype analyses.
Table 1 lists major class II HLA alleles, whether they pos-
sess any of these three markers and whether they are asso-
ciated with T1D according to published literature
[references in Table S1 (Additional file 2)].
Excellent correlation is observed between the presence of
these markers and predisposition to or protection from
autoimmune diabetes. Table 1 shows that every allele pos-
sessing all three polar markers does predispose to T1D
without exception. Secondly, in most cases alleles with
two positive markers predispose to T1D. Conversely, in
no instance does a class II HLA allele without or with only
one of these three markers associate with T1D. This simple
criterion suggests that HLA susceptibility to T1D is a func-
tion of residual charge or polarizable residues in the P9
pocket of the class II molecule.
The presence of two of three markers β9 (polar), β37
(polar) and β57 (non-Asp), score of "2" (Table 1), distin-
Table 1: The three-residue grip model of susceptibility to immune mediated diabetes
allele β9 β37 Non-Asp β57 score T1D
DRB1*0101 Hydrophobic W Polar S No 1 No
DRB1*0301 Polar E Polar N No 2 Yes
DRB1*0401 Polar E Polar Y No 2 Yes
DRB1*0402 Polar E Polar Y No 2 Yes
DRB1*0403 Polar E Polar Y No 2 No
DRB1*0404 Polar E Polar Y No 2 Yes
DRB1*0405 Polar E Polar Y Yes S 3 Yes
DRB1*0406 Polar E Polar S No 2 No
DRB1*0407 Polar E Polar Y No 2 Yes
DRB1*0408 Polar E Polar E No 2 Yes
DRB1*0409 Polar E Polar Y Yes S 3 Yes
DRB1*07 Hydrophobic W Hydrophobic F Yes V 1 No
DRB1*0801 Polar E Polar Y Yes S 3 Yes
DRB1*0901 Charged K Polar N Yes V 3 Yes
DRB1*1001 Polar E Polar Y No 2 No
DRB1*11 Polar E Polar Y/N/S/D No 2 Yes
DRB1*11 Polar E Hydrophobic, F No 1 No
DRB1*12 Polar E Hydrophobic L/F Yes V 2 No
DRB1*1301 Polar E Polar N No 2 Yes
DRB1*1303 Polar E Polar Y Yes S 3 Yes
DRB1*1401 Polar E Hydrophobic F Yes A 2 No
DRB1*1402 Polar E Polar N No 2 No
DRB1*15 Hydrophobic W Polar S No 1 No
DRB1*16 Hydrophobic W Polar S No 1 No
DRB3*0101 Polar E Hydrophobic F Yes V 2 No
DRB3*0200 Polar E Polar Y No 2 Yes
DRB5*0202 Polar Q Polar D/N No 2 Yes
DQB1*05 Polar Y Polar Y Yes V 3 Yes
DQB1*0201 Polar Y Hydrophobic I Yes A 2 Yes
DQB1*0301 Polar Y Polar Y No 2 Yes
DQB1*0302 Polar Y Polar Y Yes A 3 Yes
DQB1*0303 Polar Y Polar Y No 2 Yes
DQB1*0601 Hydrophobic L Polar D No 1 No
DQB1*0602 Hydrophobic F Polar Y No 1 No
DQB1*0603 Polar Y Polar Y No 2 No
DQB1*0604 Polar Y Polar Y Yes V 3 Yes
Polymorphic residues within pocket P9 of class II MHC alleles are scored according to whether they are polar/charged (+1), hydrophobic (0) or 
whether the conserved β57 aspartic acid is replaced (+1). A replacement at β57 Asp leaves α76 Arg free to coordinate an acidic peptide anchor in 
P9, or when the pocket is hydrophobic move out of the pocket. Two polar residues in the pocket or a polar residue and β57 aspartic acid mutation 
distinguishes between alleles that predispose to diabetes and those that do not with few exceptions. Diabetes association in column 6 is culled from 
the published literature. DR11 is listed both as a susceptibility allele and as a resistant (neutral) allele. Typing was to two significant figures; this 
obscures the nature of residue at β37.Biology Direct 2008, 3:42 http://www.biology-direct.com/content/3/1/42
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guishes between predisposing and non-predisposing mol-
ecules with remarkable accuracy. This is the general rule.
Well known high risk alleles DRB1*0301, DRB1*0401
and DRB1*1301 score at "2" due to the presence of polar
residues at β9 and β37. Other alleles strongly predispos-
ing to T1D, DRB1*0405, DRB1*0409, DRB1*0901,
DQ*0302, or DQB1*0604, have a score of "3." They pos-
sess the two polar residues as well as replacement of the
strongly conserved β57 Asp. Mouse I-Ag7 also has a score
of "3" in this scheme. The haplotype associated with the
highest risk DR3/DR4-DQ8 is consistent with this analy-
sis. On the other hand, DR7 (score of "1" due to β57 Asp
to Val mutation; β9 and β37 hydrophobic) is not predis-
posing. The protective alleles DRB1*1501 and
DQB*0602 have scores of "1" due to a polar residue at
β37. Using the strict criterion of "2" the model fails to pre-
dict in only a few instances.
The same data represented in terms of the three compo-
nents β9, β37 and β57 is even more instructive (Table 2).
The rules governing HLA association with T1D may be
stated clearly as:
1. Polar residues at both β9 and β37 accurately distinguish
between predisposing and non-predisposing class II HLA
molecules.
2. A single polar residue at β37 but not at β9 confers dom-
inant protection.
3. A hydrophobic residue at β37 offers passive resistance
(neutral).
Two polar residues at β9 and β37 are proposed as the least
common structural feature, the minimal set of polymor-
phism, in DQ and DR molecules that predispose to T1D.
Non-Asp β57 is not a risk factor by itself. Non-Asp β57 is
a modifier or additional factor that increases disease risk
in the presence of the polar pair. These three residues rep-
resent a useful set of markers for predicting HLA associa-
tion with T1D, disease risk and severity.
Implications of the hypothesis
This hypothesis employs simple physical ideas: residual
charge in a pocket, peptide-class II MHC binding affinity,
kinetics and competition are used as parameters in sus-
ceptibility or resistance to T1D. Alleles that confer suscep-
tibility to disease are predicted to bind diabetogenic
Table 2: Clustering of HLA alleles in the space defined by the polar polymorphic residues in P9
β9 β37 β57 Alleles and association with type 1 diabetes
Polar Polar non-Asp DRB1*0405, DRB1*0409, DRB1*0801,
DRB1*0901, DRB1*1303, DQB1*05,
DQB1*0302, DQB1*0604
Polar Polar Asp DRB1*0301, DRB1*0401, DRB1*0402,
DRB1*0403, DRB1*0404, DRB1*0406,
DRB1*0407, DRB1*0408, DQB1*0301,
DQB1*0303, DQB1*0603, DRB5*0200,
DRB3*0202, DRB1*1301, DRB1*11, DRB1*10,
DRB1*1402
Polar Hydrophobic non-Asp DQB1*0201, DRB3*0101, DRB1*12
Polar Hydrophobic Asp DRB1*1401, DRB1*11
Hydrophobic Polar non-Asp none
Hydrophobic Polar Asp DQB1*0601, DQB1*0602, DRB1*1501, DRB1*16, DRB1*0101
Hydrophobic Hydrophobic non-Asp DRB1*07
Hydrophobic Hydrophobic Asp none
HLA alleles are placed in the table based on whether the markers β9 and β37 are polar or hydrophobic and whether or not they retain the strongly 
conserved aspartic acid at β57. Susceptible molecules are shown in bold, neutral in normal text, and those that confer protection are shown in 
italics. All HLA molecules susceptible to autoimmune diabetes possess polar residues at β9 and β37. The combination of β9 and β37 suffice to 
describe susceptibility to type 1 diabetes, active protection or resistance (neutral). Non-Asp β57 is a modifier. DRB1*0406 has the short Ser at β37. 
DRB1*0403 may be neutral or protective. DRB1*0101 also has Ser at β37 which is not effective in conferring dominant protection. This analysis 
does not find DQ2 (DQB1*0201) to be high risk and it is proposed to be non-disposing. Disease association is taken from the literature as in Table 
1 [Table S1 (Additional file 2)].Biology Direct 2008, 3:42 http://www.biology-direct.com/content/3/1/42
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peptides strongly with slow dissociation kinetics. Protec-
tive alleles are predicted to bind less tightly but able to
compete with susceptibility alleles for diabetogenic pep-
tides. Molecules that are neutral or resistant bind poorly
or not at all.
Such tight binding susceptibility alleles have been
reported, DRB5*0101 [40,41] and DQ8 [15]. These, on
average, present a kinetically homogenous and more
organized complex. There is little entropic cost in binding
such pre-organized complexes by T cells. These need
receptors of only low to moderate affinity and are likely to
draw a broad range of T cell clones of diverse specificity. A
broad range of T cell clones elicited for diabetes predispos-
ing alleles have the potential to cross-react.
The peptide in the moderate binding protective allele such
as DQB1*0602, on the other hand, is predicted to have a
faster dissociating rate. The peptide-protective allele com-
plex is more heterogeneous in conformation and rich in
entropy. Moderately binding peptide-MHC complexes are
predicted to select only a narrow range of finely tuned,
rearranged T cell receptors of high affinity. In the ensuing
clonal dynamics, the protective T cell clones, with higher
affinity receptors, thrive against T cells with restriction on
susceptibility alleles. Peptide-MHC affinity influences T
cell proliferation, clonal expansion and deletion.
This model offers an alternative by using difference in
affinity in place of "immunodominance" and "tolerance."
Basic processes such as van der Waals interactions, hydro-
gen bond formation, covalent bonds, electrostatic interac-
tions of dipoles and stereochemical complementarity
suffice to explain most biological phenomena [42]. We
have used the biophysical analysis of the properties of
peptide-class II MHC binding to tease out the "diabe-
togenic mutations" underlying T1D and propose similar
analysis to uncover the etiological polymorphism under-
lying class HLA involvement in other autoimmune dis-
eases such as multiple sclerosis, myasthenia gravis, Graves
disease, Addison's disease and celiac disease.
Susceptibility to disease
The model suggests that increased affinity of diabetes
autoantigens to MHC molecules and hyperstable binding
are crucial variables underlying T1D. Insulin B: 9–23 pep-
tide P9 anchor in the DQ8 structure lies in a strong elec-
trostatic field and held tightly by coupled nonbonded
interactions (Figures 1 and 2). β37 Tyr coordinates the
peptide P9 Glu in a critical hydrogen bond. Tyrosine
hydrogen bonds are strong [43]. β37 Tyr exerts a strong
pull on a diabetogenic peptide acidic, polar or basic resi-
due. This is predicted to disrupt normal on-off kinetics.
The insulin B peptide will therefore have a very large
kinetic half life. A salt bridge formed between α76 Arg and
the peptide P9 Glu is similarly strong. Insulin, an impor-
tant self antigen in the pathogenesis of T1D is also
expressed in the thymus. In "thymic education" of imma-
ture T cells, or the activation of autoreactive T cells in pan-
creatic draining lymph nodes and in islets, such
prolonged confrontation, from the long half-life of
autoantigenic peptides with class II molecules, could be a
sustaining factor. This could elicit an inflammatory
response and subsequent attack by killer T cells and self
directed antibodies. High affinity binding and slow disso-
ciation rates arising from a network of nonbonded inter-
actions at P9 involving β9, β37, and α76 Arg (non-Asp
β57) are postulated to underlie HLA association with
T1D. The threshold for class II MHC association is the
presence of a polar pair of residues at β9 and β37. This
synthesis also holds for other T1D predisposing epitopes
from insulin, GAD65, IA-2 and other peptides from islet
beta cells with acidic or polar residues at P9.
Diabetes epitopes and motifs
Many diabetogenic epitopes when aligned show a high
incidence of acidic residues at their C-termini. Epitopes of
DQ8 show a preponderance of acidic residues at P1 and
P9, about 39% and 60% incidence, respectively, with typ-
ically a hydrophobic residue at P4; NOD I-Ag7 displays a
similar motif [44]. Well characterized peptides, GAD65
207–220 TNMFTYEIAPVFVLLEYVT, insulin B 9–23
SHLVEALYLVCGERG, islet cell antigen (ICA69) 33–50
TKQAFIKATGKKEDEHVV, and IA-2 961–979 FEFALTA-
VAEEVNAIL show this pattern (Table 3). Peptides from
GAD65 and insulin bind in the same frame to both DQ8
and mouse I-Ag7 [15,44,45] pointing to similarities in
their binding sites. Many of these epitopes are also pre-
sented by DR3, DR4 and DR2a (DRB5*0101) [46]. Each
shows a preference for polar – usually acidic – residues at
P9. Like DQ8 and NOD I-Ag-7, these high risk alleles pos-
sess polar residues at both β9 and 37. By comparison,
class II MHC alleles such as DR7 and DR52a that are neu-
tral or resistant to T1D show no such preference for acidic
or polar residues at P9 (Table 3). DR7 and DR52a possess
a hydrophobic residue at β37.
Zinc transporter protein, ZnT8, is a newly identified
autoantigen [47]. T1D predisposing epitopes from ZnT8
have not been defined yet. Nevertheless, consistent with
its role as a cation transporter, the sequence is rich with
acidic, basic or polar residues, especially in the terminal
regions. Potential epitopes sharing the common motif
may be derived from this.
Protection
Table 2 shows that protective alleles segregate at a score of
"1": DR15 (DRB1*15), DR16 (DRB1*16) and DQ6
(DQB1*0602). A score of "1" may be interpreted as inter-
mediate or normal binding affinity for an insulin or a sim-Biology Direct 2008, 3:42 http://www.biology-direct.com/content/3/1/42
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ilar diabetogenic peptide. Protective alleles possess a
single polar residue at β37 able to interact directly with a
polar or acidic peptide residue at P9. Given a limiting con-
centration of peptides in the cellular compartment, mole-
cules that confer dominant protection can compete
successfully with susceptibility alleles. Clones of T cells
trained on protective alleles are hypothesized to compete
successfully and bring about the contraction of clones
restricted on T1D disposing class II alleles in clonal com-
petition.
Table 3: Selected alleles, their representative peptides and motifs
Peptide Sequence and motif allele
1xx4x6xx9
CLIP peptide 81–104 LPKPPKPVSKMRMATPLLMQALPM DR3
MET proto-oncogene 724–735 LKIDLANRETSI DR3
HSP70 M leprae 261–280 DSDKNPLFLDEQLIRAEFQR DR3
HSP70 M leprae 408–427 QPSVQIQVYQGEREIASHNK DR3
SSX2 37–51 WEKMKASEKIFYVYM DR3
Tetanus toxin 830–843 QYIKANSKFIGITE DR3
Preproinsulin 78–88 QPLALEGSLQK DR4
ER-60 protease TEDEFKKFISDKDASVVG DR4
14-3-3 epsilon 57–71 RASWRIISSIEQKEE DR4
GAD65 274–286 IAFTSEHSHFSLK DR4
GAD65 471–490 VDKCLELAEYLYNIIKNREG DR4
Aminopeptidase 462–475 FELFPSLSHNLLVD DR4
β2 microglobulin 64–78 LYYTEFTPTEKDEY DR0405
der pII 58–73 IDGLEVDVPGIDPNA DR0405
HSP90 beta 68–81 KELKIDIIPNPQER DR0405
Fel d1 22–37 EQVAQYKALPVVLENA DR0405
Integrin β3 24–39 AWCSDEALPLGSPRCD DR52a
AChR alpha 144–163 MKLGTWTYDGSVVAINPESD DR52a
AChR epsilon 201–219 ENGEWAIDFCPGVIRRHHG DR52a
Lol p1 101–120 APYHFDLSGHAFGSMAKKG DR52a
Influenza A HA 306–324 PKYVKQNTLKLATGMRNVP DR7
HSP70 M Leprae 241–260 AKIELSSSQSTSVNLPYITV DR7
HIV-1 RT 326–345 FRKQNPDIVIQYMDDLYVG DR7
HLA class I α52–60 IEQEGPEYW DQ2
Flu NP 265–278 IASNENMDAMESSTL DQ2
M leprae 18 kD 31–43 DAWREGEEFVVEF DQ2
Rabies virus NP 11–24 NNQVVSLKPEIIVDQ DQ2
Thyroid peroxidase 632–645 IDVWLGGLAENFLP DQ2
Thyroid peroxidase 632–645 IDVWLGGLAENFLP DQ8
Trail receptor 2 364–380 GRFTYQNAAAQPETG DQ8
Cyclophilin R 325–340 VDQWSTETIASHEDIE DQ8
Cathepsin D 65–77 EPVSELLKNYLDA DQ8
E25B protein 112–126 YQTIEENIKIFEEDA DQ8
I-A2B 644–658 GGDPGADATAAYQEL DQ8
I-A2B 762–776 KNRSLAVLTYDHSRV DQ8
GAD65 121–140 YVVKSFDRSTKVIDFHYPNE DQ8
GAD65 231–250 PGGSGDGIFSPGGAISNMYA DQ8
GAD65 248–259 NYAMMIARFKMF DR3
GAD65 250–273 AMMIARFKMFPEVKEKGMAALPRL DQ8
GAD65 471–490 VDKCLELAEYLYNIIKNREG DR4
I-A2 961–979 FEFALTAVAEEVNAIL DQ8
I-A2 961–979 FEFALTAVAEEVNAIL DQ8
ICA69 33–50 TKQAFIKATGKKEDEHVV DQ8
Insulin B:9–23 SHLVEALYLVCGERG DQ8
Insulin B:24-C:4 FFYTPKTRREAED DQ8
Epitopes of several class II MHC molecules are aligned manually according to their pocket motif. The major diabetes susceptibility molecules DR3, 
DR4. DR405 and DQ8 show a strong preference for polar residues at position P9. Acidic residues such as Asp and Glu are common at this position 
but there are also basic and other polar residues. In contrast alleles that are neutral (DR7 and DR52a) show a preference for aliphatic and 
hydrophobic residues at P9. DQ2 shows no preference for acidic residues at P9 that characterize diabetogenic molecules. Sequence information 
comes from several sources including [46].Biology Direct 2008, 3:42 http://www.biology-direct.com/content/3/1/42
Page 9 of 16
(page number not for citation purposes)
Resistance or neutrality to disease
DRB3*0101 does not bind to T1D associated peptides. In
the structure of DR52a, β57 Val abolishes the salt bridge
at the rim of the binding site and releases α76 Arg to a
marked conformation up and away from pocket 9. β37
Phe coupled with Val at β57 strongly determines the
extreme α76 Arg conformation in the PlA1-DRB3*0101
complex (PDB code 2Q6W). These combine to make a
very hydrophobic P9 pocket and little preference for
charged or polar peptide residues at P9. The peptide bind-
ing motif (P1, P4, P9) of DR52a is [hydrophobic – polar
– hydrophobic] compared to the motif for the diabetes
associated HLA-DQ8 and the mouse counterpart I-Ag7,
[polar – hydrophobic – polar]. DR52a possesses two of
the markers, polar β9 and non-Asp β57. However, β37
Phe determines the conformation of α76 Arg. β37 Phe
also breaks the hydrogen bonding network characteristic
of diabetogenic alleles. A similar argument can be made
for DR7 and for DRB1*1401, DRB1*12 and a subset of
alleles of DRB1*11. All possess a hydrophobic residue at
β37. In the framework of our competition model, class II
molecules such as DR7, DR52a, DR12, DR14 and alleles
of DR11 with hydrophobic residue at β37 show no prefer-
ence for peptides with acidic P9. They do not bind and
cannot compete for such diabetogenic peptides. They also
cannot offer dominant protection but are resistant (neu-
tral) to autoimmune diabetes. A hydrophobic residue at
β37 renders a class II allele neutral to T1D.
The determinant role of β37
The physical chemical nature of β37 is consequential to
genetic susceptibility, resistance and protection. A hydro-
phobic residue at β37 acts as stopper and resists predispo-
sition to autoimmune diabetes. Interestingly, β37 and
β57 are correlated such that a hydrophobic residue at β37
ensures a hydrophobic residue at β57; else β57 encodes
the conserved Asp (Table 4) which forms a restraining salt
bridge to α76 Arg. Therefore a hydrophobic residue at β37
imparts a strong hydrophobic character to pocket P9. A
hydrophobic pocket P9 has no preference for acidic resi-
dues that characterize diabetogenic epitopes. The hypoth-
esized role of β37 may be discerned in a comparison of
DRB3 alleles: while DR52a (DRB3*0101; β37 Phe) is neu-
tral to T1D, DR52b (DRB3*0200) is predisposing to
autoimmune diabetes in Belgian and in Northern Indian
populations [48,49]. DR52b (DRB3*02) alleles encode a
polar group at β37, usually Tyr and occasionally Asn or
Ser, hence a preference for a basic residue in pocket P9.
These are similar to the predisposing DR3.
The nature of the polar residue at β37 is also important for
dominant protection. This may be discerned in the case of
DRB1*0406 which has a score of "2" but is protective, in
apparent disagreement with the hypothesis. DRB1*0404,
on the other hand, with a score of "2" is predisposing. The
protective DRB1*0406 possesses the short serine which is
not as effective as the long tyrosine in DRB1*0404 in
maintaining the hydrogen bond network that connects
the diabetes associated peptide residue. β37 Ser, neverthe-
less, renders pocket P9 polar. Further, in the DR2 haplo-
type, DQB1*0602 shows greater dominant protection
Table 4: Pattern of variation between β37 and β57 in class II 
MHC when β37 is hydrophobic
Class II MHC molecule β37 β57
DRB1*0701 F V
DRB1*0706 F A
DRB1*0708 V V
DRB1*0709 F V
DRB1*0809 F D
DRB1*0821 F D
DRB1*1110 F D
DRB1*1201 L V
DRB1*1204 L D
DRB1*1205 L V
DRB1*1308 L D
DRB1*1364 L D
DRB1*1401 F A
DRB1*1405 F D
DRB1*1407 F A
DRB3*0101 F V
DRB3*0301 F V
DQB1*0201 I A
DQB1*0203 I D
In class II MHC molecules, a hydrophobic residue at β37 ensures a 
hydrophobic residue at β57 or else retains the strongly conserved 
aspartic acid. In the latter case a salt bridge is maintained between β57 
Asp and the invariant α76 Arg which is thereby "latched." A 
hydrophobic β37 when coupled with a replacement of β57 makes the 
P9 pocket hydrophobic and tends to move α76 Arg out of the pocket 
as in DR52a or in DQ2. This mollifies diabetes association and 
explains the neutral association of DRB1*12 and DRB3*0101. 
Hydrophobic β37 is proposed as the basis of resistance to type 1 
diabetes.Biology Direct 2008, 3:42 http://www.biology-direct.com/content/3/1/42
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than DRB1*1501. Both are scored "1." But while
DQB1*0602 encodes β37 Tyr, DRB1*1501 has β37 Ser.
β37 tyrosine in DQB1*0602 is more effective in making a
putative single bond to the peptide acidic P9, is able to
compete better against potential predisposing alleles and
thus offers stronger protection. The presence of a single
polar residue at β37 (hydrophobic β9) capable of making
a strong interaction with an acidic or polar peptide residue
in P9 offers strong protection. Incidentally, there is no
instance of hydrophobic β9, polar β37 and non-Asp β57
(Table 2). A plausible explanation is that this combina-
tion has been selected against in MHC evolutionary his-
tory in favor of this protective role for β37.
A major implication of this hypothesis is that DQ2 is not
deemed a high risk or predisposing allele (Table 2). The
risk commonly accorded to DQ2 derives from bona fide
high risk alleles carried in the haplotype, DR3 or DQ8.
Like DR52a, a hydrophobic β37 in DQ2 renders the
pocket P9 hydrophobic and no particular preference for
negatively charged peptide anchor residues characteristic
of diabetogenic peptides [37,50]. DQ2 has isoleucine and
alanine at β37 and β57, respectively.
The analysis explains a major shortcoming of the β57
hypothesis, the observation that the DR7-DQ2 haplotype
(DRB1*0701 – DQA1*0201 DQB1*0202) does not pre-
dispose to T1D [12] though both DR7 and DQB1*0202
have non-Asp β57. Both DR7 and DQ2, however, encode
a hydrophobic β37, which explains the observation. In
comparison, the DR3-DQ2 haplotype predisposes to
T1D. DR3 possesses polar residues at both β9 and β37; the
risk is imparted by DR3. This also supports the study of
Shtauvere and colleagues who found that it is DR3 – and
not DQ2 – that is the susceptibility molecule [51], and
rationalizes the contrarian results of Kockum et al., [52]
who found DQ2 to be the more 'protective' allele with
DR3 the susceptibility factor in the DR3-DQ2 combina-
tion, and consistent with the findings of Krokowski and
coworkers [26]. DQ2 carries the DQA1*0501 α-chain.
With respect to the difference in DQ αchains, Johansen
and coworkers have shown that the α-chain has little
effect on epitope selection of DQ2 [53]. Altogether,
hydrophobic β37 is a mollifying influence on β57 replace-
ment. A hydrophobic β37 breaks the hydrogen bond net-
work that involves β9 and α76 Arg that are hypothesized
to place a firm grip on the peptide at P9 (Figure 2).
The role of β9
The role of β9 in this analysis is illustrated in DQB1*06
alleles in the transition from DQB1*0602 to *0603.
DQB1*0603 is not as protective as DQB1*0602 but not
predisposing to disease as *0604. In the DR2 haplotype,
DRB1*1501 (DR2b; β9 hydrophobic Trp, score of "1") is
protective while DR2a (DRB5; β9 polar, score of "2"; both
β9 and β37 polar) is predisposing to T1D. While DRB5 is
expressed with the protective DRB1*15/16 the protection
tendered by β37 Ser (in DRB1*15/16) is not as dominant
as with β37 Tyr in DQB1*0602.
β57 in context
The three node scheme readily accommodates the old β57
hypothesis  [12]. Interpreted through our model, the
strongly conserved β57 Asp acts as a latch that restrains
α76 Arg through the conserved salt bridge. Non-Asp β57
releases α76 Arg for a potential bond to the carboxylate
group in a T1D associated peptide but only when both
residues at β37 and β9 are polar; this increases the hold on
the peptide.
Severity and onset of disease
There is a correlation between the number of positive
markers and susceptibility to disease. The gradation poses
the question, to what extent the number of polar markers,
surrogates for electrostatics, determine severity or early
onset of clinical symptoms. The hypothesis predicts a cor-
relation between the number of the three positive markers
in the haplotype and early onset and severity of disease.
The high risk haplotype DRB1*0401 DQB1*0302 has
many of the interactions described while the protective
DRB1*1501 DQB1*0602 has few of these, and the neu-
tral DRB1*0701 DQB1*0201 is unable to form such
interactions because of the hydrophobic residue at β37.
DRB1*0901 (DR9) possesses all three markers and a very
polar P9 pocket. DRB1*0901 has the strongly polar lysine
at β9. This places a buried partial charge within pocket P9.
DRB1*0901 is unique to Asians. Likewise, the susceptibil-
ity allele DRB1*0405 has all three positive markers (β9
Glu, β37 Tyr and β57 Ser). These are associated with rapid
onset and severity of disease. Like DRB1*0901 and
DRB1*0405, DQ9, DQB1*0604 and DQB1*0401 are
prevalent in Japan. We suspect that the interactions eluci-
dated here play a role in the novel fulminant type 1 diabe-
tes reported in Japan [54].
Specific cases
DRB1*1001, DRB1*11 (DR11) and DRB1*0403 are
exceptions to the "2" threshold criterion. For DRB1*1001
and DRB1*0403, it is possible that something other than
these three markers influences features of peptide binding
that are not captured in this model, for example, the mode
of binding of the peptide, or are influenced by other mol-
ecules in the haplotype, or other pockets. With DR11, the
literature is conflicting as the genotype does not resolve
different suballeles. Both polar (Tyr, Asn, Asp and Ser)
and hydrophobic (Phe) residues are encoded at β37 in
DR11.
DQ4 (DQA1*0301-DQB1*0401) possesses β57 Asp yet is
a high risk allele. It encodes tyrosine at β37 and phenyla-Biology Direct 2008, 3:42 http://www.biology-direct.com/content/3/1/42
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lanine at β9. With a score of "1" it should be protective.
But DQ4 has the long leucine at β56. This poses steric hin-
drance in the P9 pocket that would push the α-chain away
leaving α76 Arg unpaired with β57 Asp and free to interact
with the peptide P9 residue, as in DQ8. Leucine at β56 is
rare and appears only in DQB1*0401 and DQB1*0402.
Unlatching α76 Arg gives DQ4 an effective score of "2"
(polar Tyr at β37 plus freed α76 Arg). This explanation is
corroborated by our observation that in the sequence of
the isomorphous HLA-DP molecules there is a preponder-
ance of another long residue, glutamic acid, at β56. Inter-
estingly, in this case the conserved residue at β57 is
glutamic acid (instead of aspartic acid in DQ and DR)
apparently to compensate in length for the expected salt
bridge with the invariant DP α76 Arg.
I-Ag7 and weak binding peptides
The NOD mouse is a valuable experimental model for
autoimmune diabetes; it possesses I-Ag7 as the sole class
II molecule [55]. I-Ag7 bears non-Asp β57, a structural
feature shared by DQ8. I-Ag7 and DQ8 have similar spe-
cificity for selected peptides [44] (Table 3). It has been
demonstrated that weak binding peptides with fast disso-
ciation times characterize dominant epitopes of I-Ag7. A
biological role is proposed for weak binding peptides in
escape from tolerance leading to autoimmunity [56,57].
Insulin chain B 9–23 is a dominant epitope common to
both mouse I-Ag7 and human DQ8. Insulin B 9–23 binds
I-Ag7 weakly (3–10 umol/l) with a relatively short disso-
ciation constant (< 2 hours). These observations are exam-
ined:
The shared structural characteristics between I-Ag7 and
DQ8 include polar β9 (His in I-Ag7 and Tyr in DQ8) and
polar β37 (Tyr in both I-Ag7 and DQ8) in addition to
non-Asp β57 (Ser in I-Ag7 and Ala in DQ8). The rare his-
tidine at β9 in I-Ag7 is charged and constrains the reactive
phenolic hydroxyl group of β37 Tyr through a strong
hydrogen bond of 2.92 Å, from the crystal structure of I-
Ag7 with bound HEL peptide (PDB code 1F3J; [14]). The
strong constraint on β37 Tyr by β9 His is retained in the
structure of I-Ag7 with GAD65 epitope which has nega-
tively charged Glu at P9 (PDB code 1ES0; [13]) (bond dis-
tance His NE2-Tyr OH = 2.86 Å). The structural constraint
on β37 Tyr due to charged β9 His results in a change of
rotamer in the tyrosine that prevents hydrogen bond for-
mation between β37 Tyr and the acidic residue from the
peptide (Figure 3). Histidine is notably shorter than tyro-
sine. Therefore the histidine pulls tyrosine at β37. This
effects subtle but important structural changes in pocket 9
of I-Ag7. While polar β37 Tyr and β9 His lend a polar
nature to pocket P9, β37 Tyr is not able to exert the strong,
direct pull on the acidic peptide residue at P9, as in DQ8.
β9 His constraint on β37 Tyr is also conserved (bond dis-
tance His NE2-Tyr OH = 2.64 Å) in the structure of mouse
I-Ak (PDB code 1IAK; [33]).
The stereochemical rearrangement involving β37 Tyr may
also explain the multiple preference at pocket P9 of I-Ag7
for acidic as well as hydrophobic residues and the dual
register for insulin B 9–23 [44]. Pocket 9 in mouse I-Ag7
is therefore more permissive as observed in a comparison
of the peptide repertoire of I-Ag7 and DQ8. By contrast, in
DQ8 a strong hydrogen bond is formed between β37 Tyr
and the peptide Glu (Figure 2). The multiplicity of bonds
between the insulin peptide P9 Glu and DQ8 pocket 9 is
noteworthy. Measured affinity of DQ8 with insulin B 9–
23 is ~nM and the dissociation constant > 72 hours [58]
versus ~uM and dissociation constant < 2 hours in I-Ag7
[56]. The inability of I-Ag7 to form a similar dense net-
work of bonds with the peptide negatively charged residue
likely accounts for the weak peptide binding and fast dis-
sociation times reported. It is noteworthy that histidine is
never encoded at β9 in human DQ and DR molecules.
Subtle but significant structural differences in pocket 9
due to β9 and β37 determine the difference in reactivity of
the two molecules. This calls for caution in extending
mouse I-Ag7 binding data to human class II molecules.
It may well be that weak binding dominant peptides
escape from tolerance in the thymus, as observed in I-Ag7
[56]. The counter example of strong binding of the same
insulin B epitope to DQ8 argues against this as a general
rule. It has also been demonstrated that weak binding
peptides to I-Ag7 can induce tolerance [59]. Other experi-
ments show that for either weak binding or tight binding
epitopes, altered or competing ligands are a means of
achieving tolerance. T cells specific for the altered and
competing peptides may successfully compete against T
cells that recognize dominant (or self) peptides, and thus
such altered peptides may be capable of "tolerizing" dia-
betogenic determinants. Seen in this respect weak binding
or competing peptides may be used as a strategy of devel-
oping therapies against T1D and other autoimmune dis-
eases.
Testing the hypothesis
We have shown that residual charge in pocket 9 of class II
MHC DQ and DR underlies the strong linkage between
the HLA and autoimmune diabetes. The hypotheses pre-
sented above are testable by peptide binding analyses and
by animal models. The binding affinity of diabetogenic
epitopes containing acidic residues to diabetes associated
class II molecules and those not associated (neutral or
protective) may be measured and compared. Similarly,
corresponding peptide association and dissociation kinet-
ics may be compared. In another test using the mouse
NOD model, β37 tyrosine in the lone class II molecule I-
Ag7 may be replaced by phenylalanine, another hydro-Biology Direct 2008, 3:42 http://www.biology-direct.com/content/3/1/42
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phobic residue or serine. Serine is polar but short. In
another experiment a transgenic mouse incorporating just
HLA-DQ2 could be used to test the role of β37 and
whether DQ2 confers susceptibility or resistance to T1D.
Peptides of moderate affinity are suggested as analogues
for use as competitor against diabetes associated epitopes
in class II MHC binding as a means of preventing the
autoimmune response. The optimal parameters for ana-
logue peptides may be deduced from peptide-MHC and T
cell assays. Such experiments will also be useful to deter-
mine how the relative affinity and concentration of an
analogue peptide can be used to modulate the binding
equilibrium, cytokine expression profile and T helper
phenotype appropriately for treatment.
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Reviewers' comments
Reviewer report 1
Dr. Eugene Koonin, National Center for Biotechnology
Information, National Library of Medicine, National
Institutes of Health, Bethesda, Maryland.
This is a very clear and straightforward analysis of type I
diabetes-associated polymorphisms in class II HLA mole-
cules that leads to the delineation of a minimal set of dia-
betes-associated markers. Notably, this minimal set
consists of just three amino acid positions, and Parry and
Brooks find a convincing mechanistic explanation in the
charge changes in the peptide-binding pocket P9. The
hypothesis is readily testable in straightforward peptide-
binding experiments.
Author response
We are grateful to Dr. Koonin for his review. Your other
suggestions have also improved this article. We have a
restructured and more streamlined manuscript. The paper
is much shorter.
Reviewer report 2
Dr. Michael Lenardo and Dr. Hossam Ashour, Molecular
Development Section, Laboratory of Immunology,
National Institute of Allergy and Infectious Diseases,
National Institutes of Health, Bethesda, Maryland.
The manuscript by Parry and Brooks addresses polymor-
phisms in HLA-DQ and HLA-DR as potential modifiers of
susceptibility and resistance in Type 1 Diabetes (T1D).
They employed structural, biophysical and computational
approaches and relied heavily on published literature to
propose T1D susceptibility and protective HLA-antigen
molecules. The manuscript is generally informative, with
several instances of ambiguity, as outlined below in my
report.
Major Comments:
1 – The authors focused their efforts on Insulin and did
not address other autoantigenic peptides that were shown
to be major players in T1D pathogenesis such as GAD, IA-
2, Zn transporter, and HSP. What is the reason for that?
2 – Table S1, Are there any controversies in the literature
regarding a particular allele being associated with T1D?
The authors can denote the references that are not defini-
tive (due to conflicting reports from other investigators in
the field), if any, and discuss this further in the supple-
mental section.
Author response
We would like to thank Drs. Lenardo and Ashour very
much for their comments above. They have helped to
make our paper stronger and more precise. Our approach
is structural but broadly bioinformatic and we have used
the published literature to test how general our structural/
biophysical hypothesis is.
1. The revised manuscript includes a new section "Diabe-
tes epitopes and motifs" and an additional table, Table 3.
These address and expand the hypothesis to other autoan-
tigens. We are particularly thankful for alerting us to the
role of the zinc transporter.
2. We have addressed ambiguity in the literature concern-
ing whether alleles predispose to diseases, are neutral or
protective (Table S1). This ambiguity arises mostly from
low resolution genotyping.
Reviewers
We have read the revised manuscript and find your
changes to have strengthened and clarify the work. We
believe that it is now ready for publication.
Reviewer report 3
Dr. Bhagirath Singh, Institute of Infection and Immunity,
Canadian Institutes of Health Research (CIHR), and
Department of Microbiology & Immunology, University
of Western Ontario, London, Ontario, CANADA.
This manuscript presents a hypothesis that suggests that a
minimal set of polymorphism in HLA-DQ and -DR spec-
ifies susceptibility and resistance to autoimmune diabe-
tes. The authors have done a detailed analysis of the
structural data of various class II human major histocom-
patibility (MHC) molecules and the hypothesis extends
the current understanding of the linkage between class II
MHC and type 1 diabetes (T1D). The pioneering work of
McDevitt et al [12] showed the role of beta chain Asp-57
residue of certain HLA molecules in autoimmune diabe-
tes. The present paper extends this to include beta chain
residues 9, 37 and 57. The analysis presented is logical
and supports the revised and extended hypothesis. I have
number of suggestions to improve the presentation and
interpretations presented by the authors:
1. The title and the abstract should be modified to give a
better understanding of the contents of the manuscript. I
would suggest a modified title:
"A new model defines the minimal set of polymorphism
in HLA-DQ and -DR that determines susceptibility and
resistance to autoimmune diabetes" The abstract should
include new elements that extends and improves the cur-
rent model of the role of MHC class II in autoimmune dia-Biology Direct 2008, 3:42 http://www.biology-direct.com/content/3/1/42
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betes. It should mention the role of peptide affinity for
MHC class II and its influence on T cell selection as dis-
cussed on page 20–21 (in submitted manuscript). The pro-
posed studies that may test the model could also be
mentioned.
2. Taking into account the published structure-function
studies with diabetes relevant epitopes of GAD and Insu-
lin the authors should explain if their model (involving
beta chain residues 9, 37 and 57) supports the binding to
MHC class II or functional activation of T cells with vari-
ous peptide analogs. The studies of Insulin B 9–23 or var-
ious GAD peptides binding to I-Ag7 or DQ8 will be highly
relevant.
3. It is not clear on p. 21 (in submitted manuscript) what is
meant by " in the model proposed by this report the pro-
tective molecule is predicated to bind less tightly but com-
petitively". There are recent studies (Suri A. et al Curr
Opin Immunol. 2008; 20:105–10) that showed that low
affinity peptides for MHC class II binding could induce
diabetes. These studies are relevant in making the point
that weak affinity of autoimmune epitopes for MHC class
II may control autoreactive T cell responses. The high to
medium affinity peptide specific T cells are probably
deleted in the thymic selection. Thus, how low affinity of
peptide for MHC class II may relate autoreactive T cell
selection may be important point to be discussed in the
manuscript.
Author response
1. We embrace the suggestion of Dr. Singh and adopt the
new title. We have also expanded the abstract.
2. In the model, class II MHC molecules that predispose
to autoimmune diabetes, For example, DQ8 binds (very)
tightly to diabetogenic epitopes while a protective alleles
such as DQ6.2 binds moderately (ie. with intermediate
affinity). We propose using analogues that can compete
for binding to the class II molecule. We anticipate that
such peptides need to bind only moderately but with suf-
ficient affinity to compete for the class II MHC binding
site. These would interact in an equivalent manner with
beta chain residues β9 and β37.
A simple strategy we envision is inspired by DRB1*0406.
DRB1*0406 possesses polar residues at both β9 and β37
except that β37 is Ser. The long Glu at P9 in the epitopes
listed in Table 3 ay be changed to Ser to make simple
altered ligands. In the text, we discuss how such altered
ligands are bound by class II molecules and activate T
cells. Two references we cite by Chaturvedi et al. and by
Evavold at al. [38,39] give excellent discussions about
such functional activation of T cells by peptide analogs.
More sophisticated strategies may also be used to make
peptide mimics that successfully compete with diabe-
togenic peptides, especially in alleles with non-Asp β57,
to defeat the coordination by α76 Arg. We are very thank-
ful. This comment helps to expand the scope of the paper.
A new section "Diabetes epitopes and motifs" and the
additional Table 3 address the role of GAD and other
autoantigens, and illustrate the properties of ligands that
bind HLA alleles associated with T1D.
3. You raise a very important point. The idea that weak
binding epitopes, rather than high affinity peptides,
underlie type 1 diabetes (Suri et al., Curr Op Immunol,
2008 [56]) appears to run counter to our hypothesis. First,
we try to explain this observation of weak binding pep-
tides in the mouse I-Ag7 at the level of structure. The new
section "I-Ag7 and weak binding peptides" is devoted to
this question.
But now we also see how weak affinity peptides may be
used to control autoimmunity as you suggest: we propose
analogue peptides which though weak binding may be
able to shift the equilibrium from the tight binding com-
plexes of diabetogenic epitopes and susceptibility alleles
to complexes between analogue peptides and susceptibil-
ity alleles. This strategy needs to take into account the
affinity or the relative affinity of the analogue peptide as
well as its concentration. These will have to be determined
empirically. How the two parameters influence the
cytokine profile is of interest.
Again, we are thankful for this important suggestion.
Reviewer
The manuscript has been considerably revised and
updated based upon my comments. Additional sections
have been added and new references provided. In my
view, the revised manuscript provides a new model to test
the hypothesis that in addition to residue 57, residues 9
and 37 on the beta chain provide additional sites on MHC
class II molecule for peptide presentation to CD4+ T cells.
In association with Table 1 and 2, the list of peptides and
motifs in Table 3 provides a good correlation in structure-
function. The presentation of autoantigenic peptides by
MHC class II molecules in susceptible host determines
their ability to induce protective or pathogenic T cells in
autoimmune diseases. A better understanding of the struc-
ture-function relationship of MHC class II molecules is
critical in the rational design of relevant molecules to pre-
vent autoimmune diseases.Biology Direct 2008, 3:42 http://www.biology-direct.com/content/3/1/42
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